B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
HROW
HarrowANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Harrow has improving commercial indicators: Q2 revenue rose 60% sequentially, VEVYE revenue reached $29.4 million, and IHEEZO and TRIESENCE posted record demand metrics. The bull case requires H2 conversion of demand into net revenue and EBITDA while TYRVAYA expands the portfolio.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.6.
What can break
H2 demand may not convert into reported net revenue and Adjusted EBITDA at the reiterated guidance levels.
Momentum
19
Value
56
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $43.50 · Bull $52.00 · Bear $29.00Analysis 2026-09-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $67.50
Why
Momentum19 · Δ7d -1.0
Value56 · Δ7d -0.0
Sentiment82 · Δ7d -0.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -0.6.
Contradictions & invalidation
- • H2 demand may not convert into reported net revenue and Adjusted EBITDA at the reiterated guidance levels.
- • IHEEZO pricing improvements and channel normalization may not persist as expected.
- • The first-half revenue pace was lighter than expected, VEVYE previously created gross-to-net pressure, and future value depends on execution across pricing, payer access, portfolio integration, and profitability.
Catalyst clock
2026-12-05
TYRVAYA acquisition close
Lead driver: Sentiment · See AI snapshot
Momentum
19
9% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
-8.1
Value
56
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.9
Sentiment
82
62% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-4.8
Why this grade
Composite grade A. Momentum 19.3 / Value 56.4 / Sentiment 82.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-06. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$43.50
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.48B
Beta
0.07
Shares Out
37.49M
P/E (TTM) · Derived
-282.4
P/S (TTM)
8.12
P/FCF (TTM) · Derived
337.39
Rev YoY
+10.9%
EPS YoY
-459.6%
Gross Margin
+73.3%
Op Margin
+2.1%
Net Debt
$179.05M
Current Ratio
2.24
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data